A Phase 3 interventional study of secukinumab and Placebo in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Completed at 111 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.
Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2019, is one of 6 in phase 3, and was the 2nd registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 9 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 6–100
Novartis Pharmaceuticals · Sites in Italy
Ages 18–100
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 544 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 545 across the 10 interventional studies, 125 across the 10 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
9 of the studies in Hidradenitis Suppurativa by Novartis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
| NCT06517732Novartis PharmaceuticalsStudy to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation | 2026-12-31 |
| NCT07690319Novartis PharmaceuticalsA Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients | 2027-03-15 |
| NCT05921994Novartis PharmaceuticalsLong Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa. | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 21 studies in Hidradenitis Suppurativa by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study also assessed the safety and tolerability of secukinumab.
This was a multicenter, randomized, double-blind, placebo-controlled, parallel group study with two secukinumab dose regimens in 541 patients with moderate to severe HS. The study consisted of: screening (up to 4 weeks) treatment period 1 (16 weeks, active drug or placebo) and treatment period 2 (up to 1 year all patients on active drug); there was an optional extension study (NCT04179175). Adult males and females with moderate to severe HS were included, with a diagnosis of HS greater than 1 year prior to baseline. Dosing was once every 2 weeks, or once every 4 weeks via pre-filled syringe; periodic home-dosing is included.
In Treatment Period 1, participants were randomized to secukinumab Q2W, secukinumab Q4W, placebo Q2W or placebo Q4W in 1:1:0.5:0.5 ratio. In Treatment Period 2, at the Week 16 visit participants initially randomized to placebo were switched to one of the two active dose regimens (secukinumab Q2W or Q4W), while subjects randomized to secukinumab during Treatment Period 1 continued on the same dose.
At the Week 16 visit, subjects initially randomized to placebo were switched to one of the two active dose regimens (secukinumab Q2W or Q4W), while subjects randomized to secukinumab during Treatment Period 1 continued on the same dose.
The primary objective was to demonstrate the efficacy of secukinumab compared to placebo with respect to HISCR after 16 weeks of treatment; secondary objectives were to assess difference in proportion of patients with HS flares, and proportion of patients with clinical response in HS related skin pain after 16 weeks of treatment. Key safety data was collected, along with Patient Reported Outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Secukinumab 300mg every 2 weeks
Drug: secukinumab
Secukinumab 300mg every 4 weeks
Drug: secukinumab
Placebo group to secukinumab 300mg every 2 weeks
Drug: Placebo
Placebo group to secukinumab 300mg every 4 weeks
Drug: Placebo
Secukinumab 300mg every 2 or every 4 weeks
Also known as: AIN457
Placebo 300mg every 2 or every 4 weeks
Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)
HiSCR50 at Week 16 is defined as at least a 50% decrease in Abscess and inflammatory Nodule (AN) count compared to baseline with no increase in the number of abscesses and/or in the number of draining fistulas from baseline to Week 16. The baseline is defined as the last assessment (including unscheduled visits) obtained before/on the day of the first administration of the study treatment, or on the randomization date if there had been no drug administration. This endpoint was analyzed by logistic regression.
Time frame: 16 weeks
Percentage Change From Baseline in AN50 Count at Week 16
The HS affected areas, e.g. right and left axillary (armpit), right and left gluteal ("buttock"), right and left inguinal-femoral (groin), perineal, pubic, sternal, right and left sub-mammary (breast) and others were assessed by the physician for abscesses, inflammatory nodules, draining fistulas, total fistulas, and other lesions. Inflammatory lesions, including abscesses, nodules, draining fistulae, total fistulae and other lesions were counted. The analysis method for percentage change from baseline in abscesses and inflammatory nodules (AN) count at Week 16 was an ANCOVA model.
Time frame: Baseline, 16 weeks
Percentage of Participants With Hidradenitis Suppurativa (HS) Flares
Percentage of participants who experience at least one flare over 16 weeks. A flare is defined as at least a 25% increase in abscesses and inflammatory nodules (AN) count with a minimum increase of 2 AN relative to baseline. This endpoint was analyzed by logistic regression.
Time frame: 16 weeks
Percentage of Participants Achieving NRS30
Patients achieving Numerical Rating Scale score of 30 (NRS30) at week 16, defined as at least a 30% reduction and at least one unit reduction from baseline in the Patient's Global assessment of Skin Pain (where range 0 \[no skin pain\] to 10 \[worst skin pain\]). This endpoint was analyzed by logistic regression.
Time frame: Baseline, week 16
| Milestone | Secukinumab - Q2W | Secukinumab - Q4W | Placebo | Placebo - Re-randomized to Secukinumab Q2W | Placebo - Re-randomized to Secukinumab Q4W |
|---|---|---|---|---|---|
| Started | 182 | 181 | 181 | 0 | 0 |
| Full analysis set (fas) | 181 | 180 | 180 | 0 | 0 |
| Completed | 168 | 169 | 172 | 0 | 0 |
| Not completed | 14 | 12 | 9 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 1 | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Technical problems | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 9 | 5 | 0 | 0 |
| Withdrew: Misrandomized | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Severe gcp violation | 1 | 1 | 0 | 0 | 0 |
| Milestone | Secukinumab - Q2W | Secukinumab - Q4W | Placebo | Placebo - Re-randomized to Secukinumab Q2W | Placebo - Re-randomized to Secukinumab Q4W |
|---|---|---|---|---|---|
| Started | 168 | 169 | 0 | 85 | 87 |
| Completed | 131 | 137 | 0 | 68 | 75 |
| Not completed | 37 | 32 | 0 | 17 | 12 |
| Withdrew: Adverse event | 6 | 5 | 0 | 1 | 2 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 26 | 20 | 0 | 10 | 6 |
| Withdrew: Poor efficacy | 1 | 2 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 3 | 3 | 0 | 2 | 2 |
| Withdrew: Physician decision | 0 | 2 | 0 | 1 | 1 |
HiSCR50 at Week 16 is defined as at least a 50% decrease in Abscess and inflammatory Nodule (AN) count compared to baseline with no increase in the number of abscesses and/or in the number of draining fistulas from baseline to Week 16. The baseline is defined as the last assessment (including unscheduled visits) obtained before/on the day of the first administration of the study treatment, or on the randomization date if there had been no drug administration. This endpoint was analyzed by logistic regression.
| Percentage of participants | Secukinumab 1 - Q2W | Secukinumab 2 - Q4W | Placebo |
|---|---|---|---|
| Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) | 45.0 | 41.8 | 33.7 |
The HS affected areas, e.g. right and left axillary (armpit), right and left gluteal ("buttock"), right and left inguinal-femoral (groin), perineal, pubic, sternal, right and left sub-mammary (breast) and others were assessed by the physician for abscesses, inflammatory nodules, draining fistulas, total fistulas, and other lesions. Inflammatory lesions, including abscesses, nodules, draining fistulae, total fistulae and other lesions were counted. The analysis method for percentage change from baseline in abscesses and inflammatory nodules (AN) count at Week 16 was an ANCOVA model.
| percentage change from baseline | Secukinumab 1 - Q2W | Secukinumab 2 - Q4W | Placebo |
|---|---|---|---|
| Percentage Change From Baseline in AN50 Count at Week 16 | -46.8 ± 3.33 | -42.4 ± 4.01 | -24.3 ± 4.33 |
Percentage of participants who experience at least one flare over 16 weeks. A flare is defined as at least a 25% increase in abscesses and inflammatory nodules (AN) count with a minimum increase of 2 AN relative to baseline. This endpoint was analyzed by logistic regression.
| Percentage of participants | Secukinumab 1 - Q2W | Secukinumab 2 - Q4W | Placebo 2 |
|---|---|---|---|
| Percentage of Participants With Hidradenitis Suppurativa (HS) Flares | 15.4 | 23.2 | 29.0 |
Patients achieving Numerical Rating Scale score of 30 (NRS30) at week 16, defined as at least a 30% reduction and at least one unit reduction from baseline in the Patient's Global assessment of Skin Pain (where range 0 \[no skin pain\] to 10 \[worst skin pain\]). This endpoint was analyzed by logistic regression.
| Percentage of participants | Secukinumab 1 - Q2W | Secukinumab 2 - Q4W | Placebo |
|---|---|---|---|
| Percentage of Participants Achieving NRS30 | 34.1 | 32.2 | 23.8 |
Collected over Adverse events (AEs) were reported from first dose of study treatment, up to approximately 60 weeks for AIN457 (up to 52 weeks for subjects moving to extension study) and 16 weeks for placebo.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIN457 Q2W | 0/181 (0%) | 13/181 (7.2%) | 135/181 (74.6%) |
| AIN457 Q4W | 0/180 (0%) | 9/180 (5%) | 132/180 (73.3%) |
| Placebo | 0/180 (0%) | 6/180 (3.3%) | 88/180 (48.9%) |
| Any AIN457 Q2W | 0/266 (0%) | 18/266 (6.8%) | 184/266 (69.2%) |
| Any AIN457 Q4W | 0/267 (0%) | 19/267 (7.1%) | 183/267 (68.5%) |
| Any AIN457 | 0/533 (0%) | 37/533 (6.9%) | 367/533 (68.9%) |
| Event | AIN457 Q2W | AIN457 Q4W | Placebo | Any AIN457 Q2W | Any AIN457 Q4W | Any AIN457 |
|---|---|---|---|---|---|---|
| Sweat gland infectionInfections and infestations | 1/181 | 3/180 | 0/180 | 1/266 | 3/267 | 4/533 |
| HidradenitisSkin and subcutaneous tissue disorders | 3/181 | 3/180 | 2/180 | 4/266 | 4/267 | 8/533 |
| PneumoniaInfections and infestations | 0/181 | 0/180 | 0/180 | 0/266 | 2/267 | 2/533 |
| PericarditisCardiac disorders | 0/181 | 1/180 | 0/180 | 0/266 | 1/267 | 1/533 |
| AppendicitisInfections and infestations | 0/181 | 1/180 | 0/180 | 1/266 | 1/267 | 2/533 |
| Breast cellulitisInfections and infestations | 0/181 | 1/180 | 0/180 | 0/266 | 1/267 | 1/533 |
| CellulitisInfections and infestations | 1/181 | 1/180 | 0/180 | 1/266 | 1/267 | 2/533 |
| Post procedural infectionInfections and infestations | 0/181 | 1/180 | 0/180 | 0/266 | 1/267 | 1/533 |
| Urinary tract infectionInfections and infestations | 0/181 | 1/180 | 0/180 | 0/266 | 1/267 | 1/533 |
| C3 glomerulopathyRenal and urinary disorders | 0/181 | 1/180 | 0/180 | 0/266 | 1/267 | 1/533 |
| Event | AIN457 Q2W | AIN457 Q4W | Placebo | Any AIN457 Q2W | Any AIN457 Q4W | Any AIN457 |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 33/181 | 32/180 | 14/180 | 39/266 | 46/267 | 85/533 |
| NasopharyngitisInfections and infestations | 32/181 | 24/180 | 13/180 | 40/266 | 29/267 | 69/533 |
| HidradenitisSkin and subcutaneous tissue disorders | 16/181 | 17/180 | 23/180 | 28/266 | 26/267 | 54/533 |
| DiarrhoeaGastrointestinal disorders | 11/181 | 16/180 | 9/180 | 12/266 | 24/267 | 36/533 |
| Upper respiratory tract infectionInfections and infestations | 9/181 | 13/180 | 4/180 | 12/266 | 17/267 | 29/533 |
| PyrexiaGeneral disorders | 13/181 | 8/180 | 2/180 | 16/266 | 12/267 | 28/533 |
| FatigueGeneral disorders | 6/181 | 11/180 | 8/180 | 8/266 | 13/267 | 21/533 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/181 | 6/180 | 8/180 | 14/266 | 9/267 | 23/533 |
| PruritusSkin and subcutaneous tissue disorders | 11/181 | 6/180 | 2/180 | 15/266 | 8/267 | 23/533 |
| IntertrigoSkin and subcutaneous tissue disorders | 10/181 | 7/180 | 2/180 | 11/266 | 8/267 | 19/533 |
| Age, Categorical(Participants) | Secukinumab 1 - Q2W | Secukinumab 2 - Q4W | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 178 | 177 | 179 | 534 |
| >=65 years | 3 | 3 | 1 | 7 |
| Age, Continuous(years) | Secukinumab 1 - Q2W | Secukinumab 2 - Q4W | Placebo | Total |
|---|---|---|---|---|
| Mean | 37.1 ± 12.53 | 35.7 ± 11.71 | 35.5 ± 10.75 | 36.1 ± 11.69 |
| Sex: Female, Male(Participants) | Secukinumab 1 - Q2W | Secukinumab 2 - Q4W | Placebo | Total |
|---|---|---|---|---|
| Female | 102 | 100 | 102 | 304 |
| Male | 79 | 80 | 78 | 237 |
| Race/Ethnicity, Customized(Participants) | Secukinumab 1 - Q2W | Secukinumab 2 - Q4W | Placebo | Total |
|---|---|---|---|---|
| White | 145 | 146 | 139 | 430 |
| Black or African American | 15 | 10 | 12 | 37 |
| Asian | 19 | 23 | 24 | 66 |
| American Indian or Alaska Native | 1 | 1 | 2 | 4 |
| Multiple | 1 | 0 | 3 | 4 |
Showing the first 100 of 111 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jan 2019 to primary completion in Oct 2021, 32 months.
Results were first posted in Sep 2024, 2 years 11 months after primary completion. A results delay was requested in Jul 2021.
Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 32 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab